Zogenix to advance regulatory plans on second Phase III win

Zogenix Inc. (NASDAQ:ZGNX) reported top-line data showing ZX008 as an adjunctive therapy to stiripentol regimen met the primary endpoint in its second Phase III trial, Study 1504, to treat Dravet syndrome.

Daily 0.5 mg/kg oral ZX008 led to a 54.7% greater reduction in mean monthly convulsive seizures from baseline to week 15 compared with placebo (p<0.001)...